| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2024-093 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于累计新增借款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）根据《上海证 券交易所上市公司自律监管指引第 12 号——可转换公司债券》等相关规定，现 就公司 2024 年累计新增借款情况公告如下： 一、主要财务数据概况 截至2023年末，公司经审计归属于上市公司股东的净资产为217,026.83万 元，借款余额（合并报表口径、借款本金，下同）为58,527.06万元。截至2024 年10月24日，公司借款余额（未经审计，下同）为134,930.37万元，其中：2024 年1月1日至2024年10月24日累计新增借款金额为138,278.77万元，占2023年末 归属于上市公司股东的净资产63.72%，同时本年度累计偿还贷款61,875.4 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has maintained high growth in the first three quarters, with a revenue increase of 76.51% year-on-year, reaching 12.52 billion yuan, and a net profit of 3.55 billion yuan, up 301.43% [1][2] - The gross profit margin improved to 61.0%, and the net profit margin increased to 28.01%, reflecting strong profitability [2] - The company is actively expanding its global market presence, having signed significant strategic cooperation agreements in various regions, including Europe, North America, and India, which will support future growth [3] - The company is advancing its production capacity for peptide APIs, with a new facility expected to reach a capacity of 10 tons per year by the end of 2025 [4] Financial Performance Summary - Revenue for 2024 is projected to be 1.738 billion yuan, with a year-on-year growth of 68.1% [5] - The net profit for 2024 is estimated at 461 million yuan, representing a year-on-year increase of 182.7% [5] - The earnings per share (EPS) for 2024 is forecasted to be 2.10 yuan, with a price-to-earnings (P/E) ratio of 28.9 [5] - The company’s total market capitalization is 133.25 billion yuan, with a circulating market capitalization also at 133.25 billion yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2024-092 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于公司及实际控制人之一收到中国证券监督管理委员会 立案告知书的公告 公司将积极配合中国证监会的相关工作，并严格按照监管要求履行信息披露 义务。 目前公司的经营情况正常。公司相关信息以公司在指定信息披露媒体刊登或 发布的公告为准，敬请广大投资者理性投资，注意投资风险。 特此公告。 江苏诺泰澳赛诺生物制药股份有限公司董事会 2024 年 10 月 24 日 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）及实际控制人 之一赵德中于近日收到中国证券监督管理委员会（以下简称"中国证监会"）《立 案告知书》（证监立案字 0382024093 号、证监立案字 0382024094 号）。根据《立 案告知书》，因涉嫌信息披露违法违规等，根据《中华人民共和国证券法》《 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][3] Core Views - The company reported significant growth in revenue and net profit for the first three quarters of 2024, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items reaching 1.252 billion, 350 million, and 355 million RMB respectively, representing year-on-year growth of 76%, 282%, and 301% [2] - The growth in revenue is primarily driven by the substantial increase in orders for peptide products, with the gross profit margin reaching a historical high of 73.27% in Q3 2024 [3] - The company has secured FDA DMF approvals for several raw materials and has sufficient production capacity, with plans to expand peptide production significantly by the end of 2024 and into 2025 [3] - The company has established a long-term supply contract worth 102 million USD with a major European pharmaceutical company, which is expected to accelerate delivery in the latter half of the year [3] Summary by Sections Performance Analysis - The company achieved a 301% year-on-year increase in net profit excluding non-recurring items for the first three quarters of 2024, following a doubling of revenue and a sevenfold increase in net profit in the first half of 2024 [3] - Q3 2024 revenue and net profit attributable to shareholders grew by 36% and 146% year-on-year, respectively, while the gross profit margin reached 73.27% [3] Growth Potential - The company has a robust growth outlook with high technical barriers and significant order expansion potential, having already achieved batch production exceeding 10 kg for several long-chain modified peptide drugs [3] - The company is actively expanding its production capacity for oligonucleotides and has completed the construction of a new workshop [3] Profit Forecast and Valuation - The revenue forecasts for 2024, 2025, and 2026 have been adjusted downwards by 30%, 41%, and 44% to 1.7 billion, 2.4 billion, and 3 billion RMB, respectively, while net profit forecasts have been reduced by 5%, 37%, and 43% to 450 million, 580 million, and 760 million RMB [3]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative price increase of over 20% compared to the market benchmark index within the next six months [12]. Core Insights - The company reported impressive performance in Q3 2024, with revenues reaching 1.25 billion, a year-on-year increase of 76.5%, and a net profit attributable to shareholders of 350 million, up 281.9% year-on-year [1]. - The gross margin reached a historical high of 73.3% in Q3 2024, reflecting an increase of 8.6 percentage points year-on-year [1]. - The company is accelerating its capacity expansion, with plans to add 10 tons of peptide production capacity by mid-2025, which includes the completion of two new peptide workshops [2]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 1.25 billion, with a net profit of 350 million, and a non-recurring net profit of 355 million, marking significant growth rates of 76.5%, 281.9%, and 301.4% respectively [1]. - In Q3 2024 alone, the company generated 420 million in revenue, a 36.3% increase year-on-year, and a net profit of 120 million, reflecting a 146.9% year-on-year growth [1]. - The company’s R&D investment in Q3 2024 reached 60 million, a 32% increase year-on-year, indicating a strong commitment to innovation [1]. Earnings Forecast and Valuation - The company is projected to achieve net profits of 420 million, 590 million, and 830 million for the years 2024, 2025, and 2026 respectively, maintaining previous forecasts [2]. - The corresponding price-to-earnings (P/E) ratios are expected to be 33, 23, and 16 for the same years [2]. - The revenue forecast for 2024 is set at 1.814 billion, with a growth rate of 76% [10].

Investment Rating - The report maintains a "Buy" rating for the company [2][3]. Core Views - The company reported significant growth in revenue and net profit for the first three quarters of 2024, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items reaching 1.252 billion, 350 million, and 355 million RMB respectively, representing year-on-year growth of 76%, 282%, and 301% [2][3]. - The growth in revenue is primarily driven by a substantial increase in orders for peptide products, with the gross profit margin reaching a historical high of 73.27% in Q3 2024 [3]. - The company has secured FDA DMF approvals for several raw materials and has ample production capacity, with plans to increase peptide production capacity to 10 tons per year by the end of 2025 [3]. - The company has established long-term supply contracts with major pharmaceutical companies, indicating strong future growth potential [3]. Summary by Sections Performance Analysis - The company achieved a 301% year-on-year increase in net profit excluding non-recurring items for the first three quarters of 2024, following a doubling of revenue in the first half of the year [3]. - Q3 2024 revenue and net profit attributable to the parent decreased by 11.55% and 23.47% respectively compared to the previous quarter, but still showed strong year-on-year growth [3]. Growth Potential - The company has a robust pipeline with multiple long-chain modified peptide drugs, and its production efficiency is among the industry's best [3]. - The company is expanding its production capacity and has initiated projects to enhance the quality and scale of peptide production [3]. Financial Forecasts - The revenue forecasts for 2024, 2025, and 2026 have been adjusted downwards by 30%, 41%, and 44% to 1.7 billion, 2.4 billion, and 3 billion RMB respectively, while net profit forecasts have been reduced by 5%, 37%, and 43% to 450 million, 580 million, and 760 million RMB respectively [3].

Investment Rating - The report maintains a "Buy" rating for the company [1][3] Core Views - The company reported a revenue of 1.252 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 76.51%, with a net profit attributable to shareholders of 350 million yuan, up 281.90% [2] - Gross margin improved further, with Q3 gross margin at 73.27%, an increase of 8.55 percentage points year-on-year and 5.91 percentage points quarter-on-quarter [2] - The company is expected to continue benefiting from the rapid growth of its peptide API products, with production capacity projected to reach 11.6 tons by the end of 2025, making it the leader in the domestic market [2][3] Financial Performance Summary - Total revenue (in million yuan) is forecasted to grow from 1,034 in 2023 to 1,653 in 2024, 2,355 in 2025, and 3,106 in 2026, with year-on-year growth rates of 59.90%, 42.49%, and 31.88% respectively [1][10] - Net profit attributable to shareholders is projected to increase from 438 million yuan in 2024 to 551 million yuan in 2025 and 711 million yuan in 2026, with a significant year-on-year growth of 174.14% in 2024 [1][10] - The latest diluted EPS is expected to rise from 0.74 yuan in 2023 to 2.03 yuan in 2024, 2.54 yuan in 2025, and 3.23 yuan in 2026 [1][10] Growth Drivers - The company is experiencing a rapid increase in the volume of peptide products, with a strong pipeline of orders for various peptide APIs and CDMO projects [2][3] - The demand for Oseltamivir is anticipated to rebound in Q4, further supporting revenue growth [3]

Investment Rating - The report maintains a "Recommended" rating for the company [2][4]. Core Views - The company achieved rapid growth in Q3 2024, with revenue reaching 1.252 billion yuan, a year-on-year increase of 76.51%, and net profit attributable to shareholders of 350 million yuan, up 281.90% [2]. - The peptide API business is expanding quickly, with multiple significant API orders secured globally, including collaborations in South America, the US, Europe, and India [2]. - The company is enhancing its production capacity, with the 601 and 602 peptide workshops under construction, expected to add 10 tons/year of peptide production capacity by 2025 [2]. - Future revenue projections for 2024-2026 are 1.748 billion, 2.339 billion, and 3.147 billion yuan, with corresponding net profits of 456 million, 616 million, and 877 million yuan, indicating strong growth potential [5][6]. Financial Summary - For Q3 2024, the company reported a revenue of 421 million yuan, a 36.31% increase year-on-year, and a net profit of 123 million yuan, up 146.86% [2]. - The projected revenue growth rates for 2024, 2025, and 2026 are 69.1%, 33.8%, and 34.5%, respectively [5]. - The company's PE ratios for the forecasted years are 31, 23, and 16, indicating a favorable valuation trend [5][6].

Financial Performance - The company's operating revenue for Q3 2024 reached ¥420,754,037.95, representing a year-on-year increase of 36.31%[2] - Net profit attributable to shareholders for the same period was ¥123,085,535.01, a significant increase of 146.86% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥125,293,859.06, reflecting a year-on-year growth of 176.27%[2] - Basic earnings per share for Q3 2024 were ¥0.58, up 152.17% year-on-year, while diluted earnings per share were ¥0.56, an increase of 143.48%[4] - Year-to-date operating revenue as of Q3 2024 rose by 76.51% compared to the same period last year, with substantial increases in both self-selected and customized product revenues[8] - Net profit attributable to shareholders for Q3 2024 surged by 146.86% year-on-year, reflecting the growth in operating revenue and an increase in gross margin[8] - Year-to-date net profit attributable to shareholders reached a growth of 281.90% as of Q3 2024, supported by the same factors as the quarterly performance[8] - The net profit excluding non-recurring gains and losses for Q3 2024 increased by 176.27% year-on-year, indicating strong operational performance[8] - Year-to-date net profit excluding non-recurring gains and losses grew by 301.43% as of Q3 2024, consistent with the overall revenue growth[8] - Basic earnings per share for Q3 2024 increased by 152.17% compared to the same period last year, reflecting the significant rise in net profit[8] - The net profit for Q3 2024 reached CNY 350,696,470.09, a significant increase from CNY 90,339,373.11 in Q3 2023, representing a growth of approximately 288%[18] - Operating profit for Q3 2024 was CNY 389,429,394.38, compared to CNY 121,070,282.04 in the same period last year, indicating an increase of about 222%[18] - The total profit for Q3 2024 was CNY 385,239,321.13, up from CNY 114,846,980.22 in Q3 2023, reflecting an increase of approximately 235%[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,442,609,524.32, marking a 25.24% increase from the end of the previous year[4] - The company's total assets as of the end of Q3 2024 amounted to CNY 4,442,609,524.32, up from CNY 3,547,245,952.44 at the end of Q3 2023, representing a growth of 25.2%[16] - Current assets totaled CNY 1,831,306,768.96 in Q3 2024, compared to CNY 1,494,767,183.42 in Q3 2023, indicating an increase of 22.5%[15] - The company's total liabilities increased to CNY 1,803,567,908.44 in Q3 2024 from CNY 1,357,942,277.69 in Q3 2023, reflecting a rise of 32.7%[15] - The total equity attributable to shareholders was ¥2,616,678,543.03, up 20.57% from the previous year[4] - The total equity attributable to shareholders increased to CNY 2,616,678,543.03 in Q3 2024 from CNY 2,170,268,338.07 in Q3 2023, a growth of 20.5%[16] Research and Development - The company's R&D investment totaled ¥64,227,484.08 for the quarter, accounting for 15.26% of operating revenue, a decrease of 1.37 percentage points year-on-year[4] - Research and development expenses for the year-to-date period reached 99.08 million RMB, indicating an increase due to the progress of ongoing projects[8] - Research and development expenses surged to CNY 172,750,863.81 in the first three quarters of 2024, compared to CNY 85,401,759.00 in 2023, marking an increase of 102.5%[17] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥267,304,297.88, reflecting a 13.67% increase[4] - Cash flow from operating activities for the first three quarters of 2024 was CNY 1,137,418,208.44, up from CNY 746,154,754.78 in the previous year, reflecting a growth of approximately 52%[21] - The company reported a net cash outflow from investing activities of CNY -840,263,367.82 for the first three quarters of 2024, compared to CNY -478,683,946.08 in the previous year[22] - The company received CNY 1,240,000,000.00 from investment recoveries in the first three quarters of 2024, compared to CNY 465,750,000.00 in the same period last year, indicating a substantial increase[21] Inventory and Borrowings - The company reported a significant increase in inventory, which reached CNY 521,105,440.80 in Q3 2024, compared to CNY 377,174,248.78 in Q3 2023, an increase of 38.0%[15] - The company’s short-term borrowings rose to CNY 987,828,099.87 in Q3 2024, compared to CNY 546,018,526.38 in Q3 2023, reflecting an increase of 80.7%[15] Other Income - The company reported a significant increase in other income, totaling CNY 981,200.39 in Q3 2024, compared to CNY 442,094.24 in Q3 2023[18]

江苏诺泰澳赛诺生物制药股份有限公司 （一）应当对董事会编制的公司定期报告进行审核并提出书面审核意见； （二）检查公司财务； 第一条 为规范江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"） 监事会的议事方式和表决程序，促使监事和监事会有效地履行监督职责，完善公 司法人治理结构，根据《中华人民共和国公司法》、《中华人民共和国证券法》及 《江苏诺泰澳赛诺生物制药股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，制订本规则。 （三）对董事、高级管理人员执行公司职务的行为进行监督，对违反法律、 行政法规、《公司章程》或者股东大会决议的董事、高级管理人员提出罢免的建 议； 第二条 监事会是公司的常设的监督机构，依据《公司法》等相关法律、法 规和规范性文件以及《公司章程》规定的行使职权，对公司的经营管理活动以及 董事会和高级管理人员实施监督，对股东大会负责。 （四）当董事、高级管理人员的行为损害公司的利益时，要求董事、高级管 理人员予以纠正； 第三条 监事会行使下列职权： 监事会议事规则 （一）任何监事提议召开时； （五）提议召开临时股东大会，在董事会不履行《公司法》规定的召集和主 持股东大会职责时召集和主 ...